Jackson, MS - New research suggests that mycophenolate mofetil (MMF) can be used in the management of autoimmune inflammatory myopathy. The finding, published in the March 2005 issue of Rheumatology, ...

A new study has suggested that treatment to target necroptosis in muscle fibers using a necroptosis inhibitor lessens myositis-induced muscle weakness as well as muscle cell death and inflammation in ...

Idiopathic inflammatory myopathies (IIM) represent a heterogeneous group of autoimmune disorders primarily characterised by progressive muscle weakness and inflammation, but with potential involvement ...

Despite modern medical therapies, multiorgan idiopathic inflammatory myopathies (IIM) are associated with reduced quality of life and life expectancy. A systematic review of all published ...

Idiopathic inflammatory myopathies (IIM) are a group of conditions characterized by inflammation of muscles (myositis) and other body systems. Polymyositis and dermatomyositis are subtypes of IIM.

Inflammatory myopathies are immunological diseases that lead to inflammations in muscular tissue. As of yet, little is known about the cause of these myopathies, but it is believed to be an abnormal ...

Idiopathic inflammatory myopathies (IIMs) comprise a group of inflammatory disorders in which there is chronic inflammation of skeletal muscle. This is then followed by muscle weakness. One type of ...

Please provide your email address to receive an email when new articles are posted on . Although rare, patients with idiopathic inflammatory myopathies are at an increased risk for both ischemic and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The mean annual direct and indirect costs ...

Early-onset IBM challenges age-centric diagnostic criteria, with symptoms appearing in patients younger than 46. Younger IBM patients show a higher rate of mitochondrial DNA mutations, indicating ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...